18271366. MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)

MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE

Organization Name

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor(s)

Nicole F. Steinmetz of La Jolla CA (US)

Oscar A. Ortega-rivera of La Jolla CA (US)

Jonathan K. Pokorski of La Jolla CA (US)

MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18271366 titled 'MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE

Simplified Explanation

The patent application relates to compositions, methods, and uses involving virus or virus-like particles containing epitopes of pathogens causing diseases or cholesterol checkpoint proteins.

• The invention involves compositions comprising virus or virus-like particles with epitopes of disease-causing pathogens or cholesterol checkpoint proteins.
• Methods are provided for utilizing these compositions for various purposes, such as diagnostics, vaccines, or therapeutic treatments.

Potential Applications

The technology could be applied in:

• Development of diagnostic tools for detecting specific pathogens.
• Creation of vaccines targeting disease-causing pathogens.
• Design of therapeutic treatments for diseases related to cholesterol checkpoint proteins.

Problems Solved

This technology addresses the following issues:

• Efficient detection and identification of pathogens causing diseases.
• Development of targeted vaccines for specific pathogens.
• Treatment options for diseases involving cholesterol checkpoint proteins.

Benefits

The technology offers the following benefits:

• Enhanced accuracy in diagnosing diseases.
• Targeted and effective vaccines against specific pathogens.
• Potential for personalized therapeutic treatments based on individual cholesterol checkpoint protein profiles.

Potential Commercial Applications

The technology could be commercially applied in:

• Pharmaceutical companies for vaccine development.
• Diagnostic companies for creating pathogen detection kits.
• Biotechnology firms for therapeutic drug development targeting cholesterol checkpoint proteins.

Possible Prior Art

One possible prior art could be the use of virus-like particles in vaccine development or diagnostics. Research on epitope-based vaccines may also be relevant in this context.

How does this technology compare to existing diagnostic methods for pathogen detection?

This technology offers the potential for more targeted and accurate pathogen detection, but its sensitivity and specificity compared to traditional methods need to be evaluated through further studies.

What are the potential challenges in commercializing this technology for therapeutic applications?

Commercializing therapeutic treatments based on cholesterol checkpoint proteins may face regulatory hurdles and require extensive clinical trials to demonstrate safety and efficacy.

Original Abstract Submitted

Provided are compositions, methods and uses relating to one or more virus or virus-like particle(s), each of which comprises at least one epitope(s) of a pathogen causing the disease or one or more of the cholesterol checkpoint protein(s).